Alterity Therapeutics (ASX:ATH) more than doubled after its Phase 2 results, but its still only $80m
Alterity Therapeutics (ASX:ATH) hit the jackpot last week. Any clinical-stage biotech achieving a positive Phase 2 outcome is good news, because it depicts that the company's drug is not just…
